A Hyderabad-based paediatrician has been served a legal notice by pharmaceutical companies over her social media remarks on oral rehydration products, triggering a wider debate on medical free speech, public health advocacy, and product branding in India.
Legal Notice Sparks Controversy
Dr Sivaranjani Santosh, a paediatrician known for raising concerns about sugar-laden beverages being marketed alongside Oral Rehydration Solutions (ORS), has been accused by pharma companies of making “false, misleading, and defamatory” statements about their products.
The notice, issued on March 16, specifically objects to her comments regarding ORSL (Oral Rehydration Salt and Liquid) and its rebranded variant ERZL. The companies claimed that their products comply with the Food Safety and Standards Act, 2006, and are backed by scientific evidence and regulatory approvals.
They also cited observations from the Delhi High Court, which reportedly stated that the products are “not adulterated or unsafe,” emphasizing that the dispute pertains primarily to branding rather than safety.
Regulatory Backdrop: FSSAI Action on ORS Labeling
The issue comes in the wake of action by the Food Safety and Standards Authority of India (FSSAI), which recently prohibited the use of the term “ORS” on beverage labels unless the formulation strictly adheres to standards set by the World Health Organization (WHO).
Dr Santosh had earlier raised concerns about misleading branding practices that could confuse caregivers, especially when high-sugar drinks are positioned near ORS products in pharmacies.
Pharma Companies Demand Content Removal
In the legal notice, the companies denied allegations that older ORSL products are still being sold or that ERZL is being promoted as a replacement for ORS. They also stated that distributors have been instructed to relabel or return old stock in compliance with FSSAI guidelines.
The notice demands that Dr Santosh:
- Remove social media posts deemed defamatory
- Stop using company trademarks without authorization
- Refrain from making further negative statements about their products
The companies also argued that comparing ORSL and ERZL is “baseless” and questioned the doctor’s expertise in regulatory and scientific risk assessment.
Doctor Hits Back, Calls Notice Intimidation
Responding on social media platform X, Dr Santosh strongly refuted the allegations and accused the companies of attempting to silence her.
She stated that her concerns predate and are validated by FSSAI’s October orders and pointed out that the Delhi High Court had not granted a stay on regulatory actions. She also argued that presenting ERZL as a continuation of ORSL violates the spirit of the regulatory ban and misleads consumers.
Medical Associations Condemn Legal Action
Several medical bodies have come out in strong support of the paediatrician, calling the legal notice an attempt to intimidate healthcare professionals.
The Federation of All India Medical Association (FAIMA) condemned the move, stating that doctors have both the authority and ethical duty to raise evidence-based concerns related to patient safety.
FAIMA emphasized that:
- Public health advocacy falls under the constitutional right to free speech
- Scientific debate cannot be curtailed through legal threats
- Regulatory actions already validate concerns about misleading branding
The association warned that such actions could create a “chilling effect” on doctors speaking out in the public interest.
Telangana Doctors’ Bodies Extend Solidarity
The Telangana Junior Doctors Association (T-JUDA) also opposed the notice, stating that Dr Santosh’s concerns are rooted in safeguarding child health and promoting rational medical practice.
Calling the legal action “unwarranted and deeply concerning,” T-JUDA warned that it could consider collective action if the notice is not withdrawn.
Similarly, the Telangana Senior Resident Doctors Association (T-SRDA) extended full support to the paediatrician, reaffirming the medical community’s commitment to ethical practice and patient safety.
Debate Over Free Speech and Public Health Intensifies
The incident has reignited discussions around the balance between corporate interests and medical professionals’ right to speak on public health issues. With regulatory bodies already scrutinizing product labeling practices, the case is likely to have broader implications for healthcare communication and pharmaceutical marketing in India.
